Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Revenue reached GBP 70.9m, up 11.5% year-on-year, led by A&D and Life Sciences.
  • Adjusted profit before tax rose 96.2% to GBP 5.1m; statutory PBT advanced to GBP 2.9m.
  • FY25 outlook unchanged with >95% revenue cover and leverage at 1.3x.

Gooch & Housego PLC (LSE: GHH) is a UK-based company specialising in the production of optoelectronic components, materials, systems, and advanced instrumentation for the life sciences industry. The company operates within three main sectors: Industrial, Aerospace & Defense, and Life Sciences/Bio Photonics.  GHH is listed on the FTSE AIM All-Share Index.

The company reported revenue of GBP 70.9 million in the first half of FY25, an increase of 11.5% compared with GBP 63.6 million in the prior year period. Aerospace & Defence contributed GBP 23.5 million, up 41.4%, while Life Sciences generated GBP 17.3 million, up 12.7%, with growth supported by demand for navigation instruments.

Adjusted profit before tax was GBP 5.1 million, up 96.2% year-on-year, driven by higher volumes in Aerospace & Defence and Life Sciences, and an improved product mix in Industrial markets. Statutory profit before tax increased to GBP 2.9 million from GBP 0.3 million, reflecting higher adjusted earnings, partly offset by GBP 1.9 million of restructuring and acquisition-related costs.

Business Update

On 21 July 2025, the company announced a change in its finance leadership. Chris Jewell, Chief Financial Officer, has informed the Board of his decision to step down and will leave both the Board and the company on 30 September 2025. To ensure continuity, Martin Hopcroft has been appointed Interim Chief Financial Officer, effective 28 July 2025.

Outlook

Management has maintained its expectations for FY25, noting that more than 95% of forecast revenue is already secured. The order book and segment momentum are expected to provide visibility, even in the context of external uncertainties.

In Aerospace & Defence, activity is set to benefit from higher defence budgets and new product introductions, including periscopes, laser protection filters, and ring laser gyros. Life Sciences is positioned for further growth as the Rochester facility scales new diagnostic programmes. The company also expects further margin improvements through supply chain optimisation and its outsourcing strategy. Leverage stands at 1.3x, which remains comfortably within the terms of facilities extended to 2030.

Top 10 Shareholders

The top ten shareholders of GHH collectively account for around 59.11% of the company’s total shareholding. The largest stakes are held by Odyssean Capital LLP, at approximately 12.85%, and Octopus Investments Limited, at about 11.09%.

Stock Information

As of the closing price of 12 September 2025, over the past three months, the stock has declined by approximately 3.50%, while over the six-month period, it has gained about 25.00%. The stock has a  52-week low of GBX 352.00 and a 52-week high of  GBX 660.36 and is currently trading above the average of this range.

Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels Is 12 September 2025. The reference data in this report has been partly sourced from EODHD/Others.

Technical Indicators Defined
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.